在痴呆症综合征中粉样蛋白PET阳性的患病率:元分析
Rik Ossenkoppele1, Willemijn J Jansen2, Gil D Rabinovici3
1Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands 2Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands 3Memory and Aging Center, University of Californ.
JAMA
|May 20, 2015
概括
粉样βPET成像显示斑块患病率因痴呆类型,年龄和APOE ε4状态而异. 这凸显了其在痴呆症候群中进行差异诊断的潜力,特别是老年非携带者中阿尔茨海默病 (AD) 的潜力.
科学领域:
- 神经学 神经学
- 放射学 放射学是一门学科.
- 遗传学 是一个遗传学.
背景情况:
- 胺β正子发射断层扫描 (PET) 检测纤维状斑块,这是阿尔茨海默病 (AD) 的标志.
- 粉样PET的诊断价值有限,因为斑块也出现在非AD痴呆症中.
- 对个体参与者数据的元分析对于了解不同类型痴呆症中粉样PET患病率至关重要.
研究的目的:
- 通过使用PET在各种痴呆症综合征中估计粉样蛋白阳性的流行率.
- 调查年龄和阿波蛋白E (APOE) ε4状态对粉样蛋白PET阳性的影响.
- 评估粉样PET在区分痴呆症诊断中的实用性.
主要方法:
- 来自粉样蛋白PET研究 (2004-2015年) 的个人参与者数据的元分析.
- 包括来自1359名临床诊断为AD的参与者和538名非AD痴呆症的参与者的数据.
- 用于基于诊断,年龄和APOE ε4状态来建模患病率的概括估计方程.
主要成果:
- 在AD和非AD痴呆症中,粉样蛋白阳性概率与年龄和APOE ε4状态相关.
- 在AD痴呆症中,阳性随着年龄的增长而下降,特别是在APOE ε4非载体中.
- 在非AD痴呆症中,粉样蛋白阳性通常随着年龄和APOE ε4载体的增加而增加.
结论:
- 痴呆症诊断,年龄和APOE基因型显著影响粉样蛋白PET阳性.
- 粉样PET显示了早期痴呆症差异诊断的潜力.
- 这些发现支持使用粉样蛋白PET帮助在老年APOE ε4非载体中诊断AD.
相关概念视频
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...